House approves bill expanding pharmacists' prescriptive authority after heated debate
June 25, 2026 | House of Representatives, Legislative, Delaware
This article was created by AI summarizing key points discussed. AI makes mistakes, so for full details and context, please refer to the video of the full meeting. Please report any errors so we can fix them. Report an error »
The Delaware House on June 25 passed Senate Bill 3 20, a measure that expands pharmacists' authority to prescribe certain medications and order related tests within defined parameters, arguing the change will improve timely access to care.
Representative Johnson, the bill's sponsor, told colleagues the legislation "modernizes Delaware's pharmacist scope of practice by authorizing independent prescriptive authority within clearly defined parameters," saying pharmacists are "among the most accessible health care providers in our communities." He said the bill would allow pharmacists to prescribe for conditions that do not require a new diagnosis and to follow rules the Board of Pharmacy will adopt to ensure continuity of care.
Supporters said the change aims to increase access, particularly in underserved or rural areas where getting a primary-care appointment can take days. Representative Johnson emphasized that the bill expressly excludes controlled substances except under a public-health standing order and requires communication systems so primary-care clinicians are notified of pharmacy-prescribed therapy.
Opponents pressed the sponsor on specifics. Representative Jones Giltner said she'd heard from physicians and hospital leaders who were not aware of the bill and objected to the bill's "any vs. all" language on allowable conditions, warning that a broad reading could allow pharmacists to prescribe within large, complex diagnoses without a new diagnosis. "That word needs to be changed," she said. Kate Sell of the Division of Legislative Services and Shauna Slaughter from the Division of Professional Regulation responded that the bill anticipates a one-year rulemaking process and a collaborative practice agreement framework intended to set clinical guardrails.
Other lawmakers raised conflicts of interest tied to retail pharmacy formularies and the pressure on pharmacists working in busy chain stores. Representative Collins described operational constraints, noting long lines and heavy workloads and asking whether pharmacies could meet the patient‑care demands the bill contemplates. Shauna Slaughter said the Board would have a year to adopt regulations and that participation is permissive; pharmacists who do not want to provide the services would not be forced to do so.
After extended questioning and debate, the House approved SB 320 by recorded vote, 27 yeas, 12 nays and 2 absent. The sponsor said the Office and the Board of Pharmacy will develop rules to protect continuity of care and patient safety before broad implementation.
The bill now moves to the next steps required under law for enactment and regulatory implementation.
Representative Johnson, the bill's sponsor, told colleagues the legislation "modernizes Delaware's pharmacist scope of practice by authorizing independent prescriptive authority within clearly defined parameters," saying pharmacists are "among the most accessible health care providers in our communities." He said the bill would allow pharmacists to prescribe for conditions that do not require a new diagnosis and to follow rules the Board of Pharmacy will adopt to ensure continuity of care.
Supporters said the change aims to increase access, particularly in underserved or rural areas where getting a primary-care appointment can take days. Representative Johnson emphasized that the bill expressly excludes controlled substances except under a public-health standing order and requires communication systems so primary-care clinicians are notified of pharmacy-prescribed therapy.
Opponents pressed the sponsor on specifics. Representative Jones Giltner said she'd heard from physicians and hospital leaders who were not aware of the bill and objected to the bill's "any vs. all" language on allowable conditions, warning that a broad reading could allow pharmacists to prescribe within large, complex diagnoses without a new diagnosis. "That word needs to be changed," she said. Kate Sell of the Division of Legislative Services and Shauna Slaughter from the Division of Professional Regulation responded that the bill anticipates a one-year rulemaking process and a collaborative practice agreement framework intended to set clinical guardrails.
Other lawmakers raised conflicts of interest tied to retail pharmacy formularies and the pressure on pharmacists working in busy chain stores. Representative Collins described operational constraints, noting long lines and heavy workloads and asking whether pharmacies could meet the patient‑care demands the bill contemplates. Shauna Slaughter said the Board would have a year to adopt regulations and that participation is permissive; pharmacists who do not want to provide the services would not be forced to do so.
After extended questioning and debate, the House approved SB 320 by recorded vote, 27 yeas, 12 nays and 2 absent. The sponsor said the Office and the Board of Pharmacy will develop rules to protect continuity of care and patient safety before broad implementation.
The bill now moves to the next steps required under law for enactment and regulatory implementation.
View the Full Meeting & All Its Details
This article offers just a summary. Unlock complete video, transcripts, and insights as a Founder Member.
✓
Watch full, unedited meeting videos
✓
Search every word spoken in unlimited transcripts
✓
AI summaries & real-time alerts (all government levels)
✓
Permanent access to expanding government content
30-day money-back guarantee
